CliffBio
small molecule

RYTELO

IMETELSTAT SODIUM

Loss of exclusivityJune 2039latest FDA-listed patent expiry
CompanyGeron →See this company's full patent-cliff portfolio

Drug detail

Brand nameRYTELO
Active ingredientIMETELSTAT SODIUM
StrengthEQ 188MG BASE/VIAL
Dosage formPOWDER
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalJune 2024
Marketing statusRX

Listed patents

PatentExpiresType
12171778June 2039use U-3956
12442000March 2033use U-3956
9375485March 2033use U-3956
7494982December 2026substance, product
9388416September 2026use U-3956
9388415September 2026use U-3956

Regulatory exclusivity

CodeExpires
ODE-482June 2031

More from Geron

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

RYTELO patent cliff — loss of exclusivity June 2039 | CliffBio